Hollis-Eden And NeoPHARM Gain As BioCryst Drops
The Nasdaq Biotech Index (NBI) dropped almost 1% on Monday as biotech stocks were generally on the down side.
BioCryst Pharmaceuticals (BCRX) lost more than 7% to end trading at $11.58 a share even as the company announced positive news from early phase 1 clinial trials of its Infleunza drug candidate Peramivir. The news undoubtedly was already priced into the share price, and traders were taking some profit as BioCryst stock has seen a gain of more than 30% since early August.
Hollis-Eden Pharmaceuticals (HEPH) stock gained more than 14% on the day as the company provided a positive update on its preclinical first and second generation compounds capable of maintaining hematopoietic differentation following radiation or chemo-therapy.
NeoPHARM Inc. (NEOL) shares rose more than 13% as an officer of the company purchased $20,000 worth of stock at $4.86 on September 28. (BHI's Weekly Insider Report).
_
The Nasdaq Biotech Index (NBI) dropped almost 1% on Monday as biotech stocks were generally on the down side.
BioCryst Pharmaceuticals (BCRX) lost more than 7% to end trading at $11.58 a share even as the company announced positive news from early phase 1 clinial trials of its Infleunza drug candidate Peramivir. The news undoubtedly was already priced into the share price, and traders were taking some profit as BioCryst stock has seen a gain of more than 30% since early August.
Hollis-Eden Pharmaceuticals (HEPH) stock gained more than 14% on the day as the company provided a positive update on its preclinical first and second generation compounds capable of maintaining hematopoietic differentation following radiation or chemo-therapy.
NeoPHARM Inc. (NEOL) shares rose more than 13% as an officer of the company purchased $20,000 worth of stock at $4.86 on September 28. (BHI's Weekly Insider Report).
_
posted by Nico at
8:47 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home